Experimental gene injection aims to save sight in rare retinal disorder
NCT ID NCT07656753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a gene therapy called PUMCH-E111 for a rare inherited retinal disease caused by RLBP1 mutations. Six adults aged 18-55 will receive a single injection into the eye at a low or high dose. The main goal is to check safety, but researchers will also measure changes in vision and light sensitivity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PUMCH-E111 gene therapy injection
- What this could lead to
- If successful, this could point toward a treatment that slows or partially reverses vision loss in people with RLBP1-related retinal dystrophy.
- What could go wrong
- This is a very early, small trial (6 people) focused on safety, not proof of effectiveness. The therapy may not improve vision and could cause side effects like eye inflammation or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.